Newsletter | October 29, 2019

10.29.19 -- Evotec, Integra Holdings And Yissum Establish LAB555 To Fast Track Early-Stage Drug Development


Formulation and tech transfer present perennial challenges for biopharma. That's why they're focal points at Catalent. Learn how we're leveraging state-of-the-art automation technologies to enable high-throughput formulation development and how we are applying innovative approaches to process management to address equipment and materials challenges during tech transfer.

Industry Insights
In-House Versus Outsource: A Decision-Making Guide
White Paper | By B. Rosenblatt, Ph.D., SME Biotech Consulting and D. Kenyon, Ph.D., Thermo Fisher Scientific

Biopharma executives must consider how outsourcing fits into their development and production strategy. Here’s a step-by-step guide to help make that decision.

Concentration And Ligand-Binding Analyses In Late-Stage Development And Quality Control Of Biotherapeutics
White Paper | GE Healthcare Life Sciences

Review the use of Biacore for active concentration measurements, target binding, and Fc receptor (FcR) analysis along with the use of these assays for assessment of drug potency and stability.

Optimizing Clinical Outcomes For Challenging Molecules With Lipid-Based Drug Delivery Systems
Article | Catalent

This article takes an in-depth look at how lipid-based drug delivery systems can be used as a bioavailability enhancing technology, as well as the softgel dosage form for their delivery.

Challenges And Opportunities In The Development Of Biologic Drugs
Webinar | Dassault Systemes Americas

With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins.

Most Popular News
Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.